Supply of Demazin Day & Night Cold & Flu tablets by Merck Sharp & Dohme (Australia) Pty Limited

Overview

The Therapeutic Goods Act 1989 was enacted to provide for the regulation of therapeutic goods in Australia, thereby ensuring their quality, safety, and efficacy. The Act was introduced to address the need for a comprehensive legislative framework that governs the approval, manufacture, and distribution of therapeutic goods, including medicines, medical devices, and blood products. Enacted by the Parliament of Australia, the policy objective of the Act is to protect public health by ensuring that therapeutic goods available in Australia are of an acceptable standard and that information provided about these goods is accurate and reliable. This particular gazette, C2013G00643, issued under the authority of the Therapeutic Goods Act 1989, demonstrates the Act's role in providing flexibility and oversight in specific cases where minor label discrepancies exist. In this instance, Mayada Kaylali, as a delegate of the Secretary to the Department of Health and Ageing, granted consent for Merck Sharp & Dohme (Australia) Pty Limited to supply Demazin Day & Night Cold & Flu tablets under certain conditions. This action underscores the Act's aim to balance regulatory compliance with practical considerations in the pharmaceutical industry, ensuring that public health is safeguarded while allowing for operational adjustments.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood products. This Act applies to all entities involved in the supply, manufacture, or importation of these goods within Australia. The scope of this particular legislation extends to granting specific consent for deviations from prescribed regulatory requirements, which in this case concerns the labelling of a therapeutic product. The consent granted under sections 14 and 14A of the Act applies specifically to Merck Sharp & Dohme (Australia) Pty Limited, allowing them to supply a batch of Demazin Day & Night Cold & Flu tablets with a label that does not comply with the stipulated requirements under the Therapeutic Goods Order No. 69. This consent is limited to the batch number BR961 and is subject to several conditions, including that the product adheres to all other label requirements, includes the name and address of the previous sponsor, and ensures re-direction of any customer inquiries from the previous sponsor's address to the current sponsor's address. This demonstrates the Act's ability to provide tailored regulatory flexibility while maintaining stringent control over therapeutic goods in Australia.

Key Provisions

Section 14 of the Therapeutic Goods Act 1989 (the Act) allows a delegate of the Secretary to the Department of Health and Ageing to give consent for a specified therapeutic good to be supplied in a way that does not fully comply with the standards set by the Therapeutic Goods Administration (TGA). In this case, section 14A specifically addresses the consent for a product to be supplied with a label that does not comply with the requirements under the Therapeutic Goods Order No. 69 – General requirements for medicine labels. The delegate, Mayada Kayali, has granted consent for Merck Sharp & Dohme (Australia) Pty Limited to supply Demazin Day & Night Cold & Flu tablets AUST R 133205, provided that the label does not include the name and address of the current sponsor or supplier of the goods, which is a requirement under subclause 3(2)(l) of the Therapeutic Goods Order No. 69. The consent issued under section 15(1) of the Act is conditional. Firstly, it applies only to the specific batch number BR961. Secondly, the product must comply with all other aspects of the Therapeutic Goods Order No. 69 – General requirements for medicine labels. Additionally, the product labels must include the name and address of the previous sponsor, Shering-Plough Pty Ltd. Furthermore, Merck Sharp & Dohme (Australia) Pty Limited must ensure that any contact made in relation to the product is redirected to the address of the current sponsor. The obligations imposed by this consent on Merck Sharp & Dohme (Australia) Pty Limited are clear and specific. The company must ensure that the product supplied is limited to the batch number BR961 and that it meets all other labelling requirements under the Therapeutic Goods Order No. 69. The label must include the name and address of the previous sponsor, Shering-Plough Pty Ltd, and any contact related to the product must be redirected to the current sponsor. These obligations are designed to ensure that the therapeutic good is supplied in a manner that maintains compliance with the therapeutic goods legislation while addressing a specific labelling issue. The consequences of breaching the conditions of the consent are not explicitly stated in the consent notice itself, but generally, under the Therapeutic Goods Act 1989, breaches of the Act or the Therapeutic Goods Regulations can lead to both civil and criminal penalties. For example, supplying therapeutic goods that do not comply with the regulations can result in fines or imprisonment. The specific penalties can vary depending on the nature and severity of the breach. The Therapeutic Goods Act 1989 also allows for the imposition of pecuniary penalties for breaches, which can be substantial. Thus, Merck Sharp & Dohme (Australia) Pty Limited must adhere strictly to the conditions of the consent to avoid any potential legal ramifications.